Prostate Cancer

Nearly 100% of patients with clinically localized prostate cancer, detected by PSA testing, survive at an average 10 years’ follow-up, regardless of whether they had active monitoring, radical prostatectomy, or radiotherapy, according to new study results.

Results from a multicenter study show progression-free survival in 97% of low- and intermediate-risk prostate cancer patients.

Findings from a recent study indicate that CTCs detected in blood have the potential to reveal important genetic information that could guide treatment selection.

Another study suggests that hemiablation with high-intensity focused ultrasound is a promising treatment for unilateral localized prostate cancer.

New research suggests that urologists can use the Decipher genetic test (GenomeDx Biosciences) to improve predictions of death risk from prostate cancer at10 years after prostatectomy.

Recent data show that a low-carbohydrate diet may have significant positive effects in men on hormonal therapy for prostate cancer, including metabolic effects. In this interview, study author Stephen J. Freedland, MD, discusses his group’s findings, ongoing research on diet and lifestyle changes in men with prostate cancer, and how he counsels patients.

In this interview, Dr. David Albala sits down to discuss his award-winning poster on live-cell phenotypic biomarkers at the 2016 AUA with Urology Times Editorial Consultant, Dr. J. Brantley Thrasher.

Three urologists give their take on the frequency of patients presenting with prostate cancer.

Urologist Henry Rosevear, MD discusses his thoughts on PSA screening and the recent increase in patients presenting with metastatic disease.

The authors of a recent research letter reported a 6% drop in incidence rates for early-stage prostate cancer in men 50 years of age and older from 2012 to 2013.

A recent study suggests that a man’s race/ethnicity might influence decisions about undergoing treatment and re-biopsies.

Although various calculators are available for predicting biopsy results in men with prostate cancer being managed by active surveillance, a novel model developed by researchers at Johns Hopkins University is unique for its ability to predict a patient’s “true cancer state”; ie, the Gleason score that would be assigned on whole-gland analysis after radical prostatectomy.

As interest in using multiparametric MRI as a diagnostic tool for prostate cancer increases, urologists should know that a negative mpMRI does not rule out significant prostate cancer, researchers advised at the AUA annual meeting in San Diego.

A slow breathing technique guided by an iOS application was able to reduce the occurrence of vasomotor symptoms in a small study of prostate cancer survivors treated with androgen deprivation therapy.

Clinical outcomes of men with metastatic castration-resistant prostate cancer treated with enzalutamide (XTANDI) after chemotherapy correlate with health-related quality of life both at treatment initiation and its change longitudinally, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.

A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.

A study reporting an increase in the number of men initially presenting with metastatic prostate cancer has been the source of controversy since its July publication.

We spoke to Gerald L. Andriole, MD, Michael Koch, MD, Herbert Lepor, MD, Mani Menon, MD, and Joel Nelson, MD, about the highly anticipated study findings.

For men with high-risk pathology at radical prostatectomy, exposure to results of a genomic test that classifies 5-year risk of metastasis reduces decisional conflict, according to findings of a prospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.

In this interview, Mark A. Moyad, MD, MPH, discusses non-drug interventions for urologic conditions, the difference between prescription drugs and nutraceuticals, and why a heart-healthy diet is a prostate-healthy diet.

"Avoiding unnecessary biopsies should be a high-priority goal for us all," writes J. Brantley Thrasher, MD.

An ongoing phase II trial investigating abiraterone acetate (ZYTIGA) and enzalutamide (XTANDI) as treatment for men with chemotherapy-naïve metastatic castrate-resistant prostate cancer is aiming to characterize the effects of these targeted hormonal therapies on cognition and mood.

Multiparametric magnetic resonance imaging (mpMRI) identifies a significant percentage of men who present with an elevated serum PSA level who may safely avoid prostate biopsy, British researchers report.

This review focuses on primary prevention of BPH and prostate cancer.

Sexual function/dysfunction topics discussed at the 2016 AUA included the findings of multiple studies on the effects of collagenase clostridium histolyticum (Xiaflex) treatment for Peyronie's disease, causes and treatments for ED, along with a study on patient satisfaction with implantable penile prostheses.